Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Neutral 69.3%

Neg 0% Neu 69.3% Pos 0%

Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $23 to $20.